On Monday 27 February the ABPI is hosting a parliamentary event discussion on innovation and commercial success that will be hosted by Andrew Miller MP.
The event, due to be held at the Attlee Suite of Portcullis House at the Houses of Parliament, is being held to highlight the launch of the Science in Parliament Spring Issue, which features a number of articles examining current issues and developments in the bio-pharma sector. Science in Parliament is the Journal of the Parliamentary and Scientific Committee.
Join Andrew Miller MP as he discusses why innovation and commercial success are so important to the UK, ABPI CEO Stephen Whitehead who will focus on innovation in pharma, Lord Drayson who will examine the role of innovation in other industries, and Bettina Fitt of GE Healthcare who will provide the perspective of a global innovative company.
Stephen Whitehead, CEO of the ABPI, said:
“The parliamentary event discussion and the launch of the Science in Parliament Spring Issue both serve to highlight how important innovation is: Innovation is fundamental for the on-going success of our industry, it is critical to the future wellbeing of our healthcare economy, and it is the key to fulfilling future unmet clinical need.”
The Science in Parliament Spring Issue will include the following articles, which are available for review on request:
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: [email protected]
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.